US-based medical device company CHF Solutions has signed a distribution agreement with SysteMedic to make its ultrafiltration therapy available for patients in Israel and Palestine.

It is the company’s second distribution partnership in the Middle East region and it expands the commercial availability of Aquadex SmartFlow ultrafiltration therapy to 16 countries outside the US.

Aquadex SmartFlow system is a fluid management platform. The system uses ultrafiltration to stabilise patients, experiencing fluid overload, and enable providers to manage their patients’ fluid balance with precision, control and ease.

Approximately 2% of the Israeli population is estimated to suffer from heart failure, while 90% of hospitalisations among heart failure patients are due to the signs and symptoms of fluid overload.

CHF Solutions chairman and CEO John Erb said: “CHF Solutions is committed to making ultrafiltration therapy available for patients throughout the world. Our partnership with SysteMedic demonstrates continued execution on that strategy.

“Subject to regulatory approval, we look forward to working with SysteMedic to make the simple, flexible and smart Aquadex SmartFlow system available to patients in Israel and Palestine, suffering from fluid overload due to heart failure, cardiovascular surgery and other critical care conditions.”

Commenting on the agreement, SysteMedic general manager Arik Yanco said: “We are very excited to work with CHF Solutions to introduce their ultrafiltration technology to Israel and Palestine.”

“We believe the Aquadex therapy will make a difference in the quality of lives of patients and look forward to a successful partnership.”

Israel-based SysteMedic imports and markets medical products and technologies to hospitals, health services, private clinics, home care, government and military customers in Israel and Palestine.